🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Primary Objectives: * To evaluate the safety and tolerability of isatuxima...
Status
Completed
Location
~Banner MD Anderson Cancer Center Site Number : 8400005
Start Date
2019-08-06
Trial ID
NCT04045795
Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 n...
Status
Unknown
Location
CHU Poitiers
Start Date
2020-08-28
Trial ID
NCT04287855
Treatments Being Tested
Primary Objectives: Phase 1 -To characterize the safety and tolerability ...
Status
Terminated
Location
Investigational Site Number :2500005
Start Date
2018-12-11
Trial ID
NCT03769181
Treatments Being Tested
The purpose of this clinical trial is to learn how the experimental medicin...
Status
Terminated
Location
Keck Hospital of USC
Start Date
2018-05-14
Trial ID
NCT03530683
Primary Objectives: * Phase 1: To characterize the safety and tolerability...
Status
Terminated
Location
Investigational Site Number :8400003
Start Date
2020-06-18
Trial ID
NCT04294459
Primary Objectives: * Safety run-in Part: To confirm the recommended dose ...
Status
Active Not Recruiting
Location
UCLA Site Number : 8400010
Start Date
2020-06-16
Trial ID
NCT04270409
This study is to evaluate the combination of isatuximab, iberdomide, bortez...
Status
Not Yet Recruiting
Location
Beth Israel Deaconess Medical Center (BIDMC)
Start Date
2026-06-26
Trial ID
NCT07601100
Treatments Being Tested
The goal of this clinical trial is to learn if anitocabtagene autoleucel fo...
Status
Recruiting
Location
Hospital Germans Trias i Pujol (ICO BADALONA)
Start Date
2025-06-30
Trial ID
NCT07045909
Overall the issue of patients above 65-70 years of age being that it is imp...
Status
Active Not Recruiting
Location
CHU Poitiers
Start Date
2021-07-17
Trial ID
NCT04751877
Treatments Being Tested
This is a randomized, multicenter, Phase 3, open-label study evaluating sub...
Status
Active Not Recruiting
Location
Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028
Start Date
2022-06-23
Trial ID
NCT05405166